It's truism in spine that 4% of patients rack up 75% in costs, and expensive BMP products, which are highly successful at enhancing fusion rates, are the "high octane" products for more difficult cases-high-risk patients or the obese, for example. The market needs a product for the majority of cases, believes the founder of CeraPedics LLC, and he believes his company has it in its P-15, a growth factor that's a small peptide.
12860 West Cedar Drive, Suite 101
Lakewood, CO 80228
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
